Oxford Cannabinoid Technologies

What We Could Verify

Oxford Cannabinoid Technologies Holdings plc is a publicly traded United Kingdom biotechnology company Strong evidence^[1] headquartered in Oxford. It listed on the Main Market of the London Stock Exchange in May 2021 under the ticker OCTP, raising approximately £16.5 million at IPO Strong evidence^[1]. The company is registered as a pharmaceutical development firm focused on cannabinoid-derived therapeutics, not as a cannabis cultivator, dispensary, or consumer wellness brand.

The operating subsidiary, Oxford Cannabinoid Technologies Ltd, sits beneath the listed holding company. Ownership is dispersed across institutional and retail shareholders rather than held by a parent corporation Strong evidence^[2].

As of October 2026, no product marketed under the Oxford Cannabinoid Technologies name has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), European Medicines Agency (EMA), or US Food and Drug Administration (FDA) Strong evidence.

Corporate and Pipeline Changes

The company announced significant portfolio changes after IPO. In 2023, it divested its original lead asset—a synthetic CB2-selective compound originally licensed from Canopy Growth—and refocused on a different candidate for trigeminal neuralgia Strong evidence^[2]. In 2024, the company announced a strategic review that indicated potential changes to business direction Strong evidence^[2].

These shifts are typical of early-stage biotech but should prompt caution: any description of OCT from 2021–2022 press coverage may not reflect the current company strategy. Verify the latest regulatory announcements on the London Stock Exchange before citing OCT in investment, research, or medical contexts.

The company has disclosed multiple leadership transitions via Regulatory News Service (RNS) filings Strong evidence^[2].

Why the Name Alone Is Not Evidence

If you encounter a product labelled 'Oxford Cannabinoid Technologies,' 'OCT,' or similar, do not assume it is authentic or connected to the listed biotech. Cannabis and CBD product naming is largely unregulated outside clinical contexts Weak / limited, and third-party retailers routinely use ambiguous or misleading brand names. The LSE-listed company does not manufacture or sell consumer cannabis flowers, oils, vapes, or wellness products. Any such item claiming OCT branding would not be a genuine product from the pharmaceutical company and should be treated as a third-party product making an unverified claim.

Strain and product names in general are not reliably indicative of contents, genetics, or quality; only lab testing and verifiable sourcing provide evidence Strong evidence^[3].

What to Check If You See It for Sale

If a retailer or online vendor claims to sell a product branded as 'Oxford Cannabinoid Technologies' or with any Oxford/OCT branding:

1. Certificate of Analysis (CoA). Request a third-party lab test from an accredited cannabis testing facility. A real CoA names the testing lab, batch date, and cannabinoid content measured by HPLC or GC. Absence of a CoA is a red flag Strong evidence^[3].
2. Breeder or manufacturer information. Who actually grew or produced the product? The LSE-listed Oxford Cannabinoid Technologies does not cultivate or package consumer goods; any legitimate product would have a separate cultivator or manufacturer named.
3. Batch test results. Verify the test covers residual solvents, microbial contamination, and pesticides—not just cannabinoid levels Strong evidence^[3].
4. Retailer legitimacy. Is the retailer licensed in a legal cannabis market? Check local regulatory databases (e.g., UK Cannabis Tracking System for licence holders, or state-level regulatory bodies in North America).
5. Official company statement. Contact the London Stock Exchange–listed company directly via its investor relations page to ask whether any consumer products bearing its name are authorised. As of October 2026, the answer is no.

If none of these checks resolve to verifiable information, the product is likely misbranded or fraudulent.

Similar Documented Companies

For comparison, here are other UK and international cannabis or cannabinoid-focused businesses with verifiable public documentation:

• Cansativa — UK cannabis clinic and supplier with MHRA-registered products
• Grow Pharma (Grow Group) — UK medical cannabis producer
• Organigram — Canadian licensed cannabis producer
• Jushi Holdings — Multi-state US cannabis operator
• Ascend Wellness Holdings — US cannabis retailer and cultivator

Unlike OCT, these businesses have publicly verifiable product lines, retail distribution, or licensing records. Use them as a model for what verifiable cannabis company documentation looks like.

Report Missing or Incorrect Information

If you have verifiable information about Oxford Cannabinoid Technologies—such as a breeder record, lab report, company filing, or press release that contradicts or extends this profile—please flag an error via the Weedpedia website. Include the source (URL, DOI, or official document) so we can update the record.

This profile was last verified in October 2026. Corporate status, pipeline, and regulatory approvals change; check the company's latest RNS announcements on the London Stock Exchange and its annual report for the most current information.

Sources

How this page was made

Related

• Cannabinoid Testing Methods — An overview of how labs measure THC, CBD and other cannabinoids in cannabis.
• Cansativa — German medical cannabis wholesaler and exclusive distributor of state-cultivated cannabis.
• Grow Pharma (Grow Group) — UK medical cannabis importer and distributor; verification status uncertain.
• HPLC vs GC for Cannabinoid Testing — Two chromatography methods, one key difference: heat and what it reveals about cannabinoid...
• Jushi Holdings — Publicly traded US cannabis operator with retail and cultivation in multiple state markets...
• Organigram — Publicly traded Canadian LP with major BAT ownership stake and multi-brand portfolio.